Stiris Research Inc. collaborates with US biotech to conduct their Phase III Global Parkinson’s Study
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announce it has entered into a Master Services Agreement (the “MSA”) with a US biotech company to spearhead their global Phase III trial in Parkinson’s disease (PD).
“We are excited to be collaborating with and working alongside a company that will be taking their product into Phase III globally and has the potential to be the first new treatment modality for PD in more than 20 years.” Amanda Carrera, Vice President, Stiris Research Inc.
Parkinson’s disease is the second most common neurodegenerative disorder and mainly affects the motor system. PD worsens and non-motor symptoms become more common. An estimated one million people will be living with PD in the United States by 2020, and approximately 60,000 Americans are diagnosed with PD each year (www.Parkinson.org).
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: